Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

16.37 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 16.37
Bid (Size) 13.95 (1)
Ask (Size) 18.50 (1)
Prev. Close 16.37
Today's Range 16.37 - 16.37
52wk Range 14.15 - 32.59
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-46.95%
-46.95%
1 Month
+14.16%
+14.16%
3 Month
+1.74%
+1.74%
6 Month
+8.48%
+8.48%
1 Year
-25.99%
-25.99%

More News

Read More
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Via MarketBeat
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts
Via Benzinga
A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals
Via Benzinga
Expert Ratings For ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
What's Going On With ACADIA Pharmaceuticals Stock?
Via Benzinga
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Via Benzinga
Ryan Reynolds Announces More to Parkinson’s® Campaign
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
From Acadia Pharmaceuticals Inc.
Via Business Wire
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.